Weingrill C O, Mussio W, Moraes C R, Portes E, Castro R C, Lengyel A M
Department of Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil.
Fertil Steril. 1992 Feb;57(2):331-5. doi: 10.1016/s0015-0282(16)54840-7.
To compare the effect of Parlodel SRO (Sandoz, Basel, Switzerland), a long-acting oral bromocriptine, to Parlodel (Sandoz) and to study the chronic effects of Parlodel SRO.
The study was twofold: (1) random, double-blind and (2) open.
Patients were studied in an academic environment.
Hyperprolactinemic patients were selected. Sixteen patients were treated during 1 month. Ten patients completed the 1-year follow-up.
Parlodel SRO or Parlodel was administered during 1 month (first 15 days: 5 mg/d; afterwards: 10 mg/d). Parlodel SRO was given during 1 year in variable doses (maximal 20 mg/d).
Prolactin (PRL) levels, clinical improvement, and side effects were evaluated.
After 1 month, 63% of the patients in both groups had normal PRL and 43% had menses. Side effects were similar. After 1 year all patients except one had normal PRL levels, and 89% were ovulating.
The efficacy, tolerability, and long duration of action of Parlodel SRO make it an excellent alternative for the treatment of hyperprolactinemic patients.
比较长效口服溴隐亭Parlodel SRO（瑞士巴塞尔山德士公司生产）与Parlodel的疗效，并研究Parlodel SRO的长期效应。
该研究分为两部分：（1）随机、双盲；（2）开放试验。
在学术环境中对患者进行研究。
选取高泌乳素血症患者。16名患者接受了为期1个月的治疗。10名患者完成了1年的随访。
给予Parlodel SRO或Parlodel治疗1个月（前15天：5毫克/天；之后：10毫克/天）。给予Parlodel SRO治疗1年，剂量可变（最大20毫克/天）。
评估泌乳素（PRL）水平、临床改善情况和副作用。
1个月后，两组中63%的患者PRL水平正常，43%的患者月经来潮。副作用相似。1年后，除1名患者外，所有患者的PRL水平均正常，89%的患者排卵。
Parlodel SRO的疗效、耐受性和长效作用使其成为治疗高泌乳素血症患者的极佳选择。
